SCHEMBL20155669

SCHEMBL20155669

CCc1cccc(-c2cocn2)c1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 4/20 0.37
LTB4R Q15722 1/20 0.37
LTB4R2 Q9NPC1 1/20 0.37
SCN9A Q15858 2/20 0.36
IMPDH1 P20839 1/20 0.36
CASP6 P55212 1/20 0.34
EGFR P00533 1/20 0.32
DRD2 P14416 1/20 0.32
PPARG P37231 1/20 0.32
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32
RAB9A P51151 1/20 0.32
APLNR P35414 1/20 0.31
GABRA1 P14867 2/20 0.31
GABRB2 P47870 2/20 0.31
ELANE P08246 1/20 0.31
EDNRB P24530 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27172748 0.79 IMPDH2 (0.39) IMPDH2LTB4RLTB4R2SCN9AIMPDH1
SCHEMBL20150097 0.77 SCN9A (0.36) IMPDH2LTB4RLTB4R2SCN9AIMPDH1
SCHEMBL21376005 0.75 RAB9A (0.40) DRD2NPC1RAB9AGABRA1GABRB2
SCHEMBL24498568 0.73 TYK2 (0.41)
SCHEMBL17198826 0.73 CCNT1 (0.40) CASP6EGFR
SCHEMBL20230857 0.73 TUBB4A (0.36) CASP6DRD2KDM4ENPC1RAB9A
SCHEMBL17198791 0.73 SMN1; SMN2 (0.44) LTB4RLTB4R2SCN9ACASP6KDM4E
SCHEMBL17198731 0.73 CLK4 (0.39) CASP6DRD2KDM4ENPC1RAB9A
SCHEMBL21375829 0.73 ADRA2A (0.34) DRD2KDM4ERAB9AGABRA1GABRB2
SCHEMBL20230841 0.73 CASP6 (0.33) CASP6DRD2KDM4ENPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 IMPDH2 4304/4885LTB4R 3427/4885LTB4R2 3044/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 IMPDH2 4304/4885LTB4R 3427/4885LTB4R2 3044/4885
US-10647713-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 IMPDH2 4304/4885LTB4R 3427/4885LTB4R2 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.